Dan Vasella may be smarting that India won’t extend a wider patent for his Gleevec cancer med, but Wyeth’s R&D chief isn’t worried such moves bode ill for big pharma. After inaugurating a new $10 million, R&D facility in Hyderabad, Bob Ruffolo told The Business Standard that its’ time to think beyond maintaining only research operations in India.

He’s looking at making drugs in India, too. “We are starting to look at manufacturing operations in India for both APIs and new drugs,” he says. And so while the Novartis ceo sulks in Switzerland and vows to switch hundreds of millions of dollars in investments to China, rivals are looking at moving into that other big market Dan wants to forsake. Maybe Vasella’s retaliatory decision should be reconsidered?